JMP Reaffirms Price Target for Madrigal Amid Rezdiffra Growth Potential

Madrigal Pharmaceuticals (NASDAQ:MDGL) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. With a price target of $470, Citizens JMP analysts reiterated their Market Outperform rating for Madrigal Pharmaceuticals (NASDAQ:MDGL) on June 5. The analysts discussed future developments that would affect the company’s prospects.

On June 7, Madrigal Pharmaceuticals was scheduled to hold a product theater called “Clinical Deep Dive: Unlocking the Treatment Potential of Rezdiffra.” It was expected that this event would offer insight into the early experiences of the endocrinology community with Rezdiffra, the first medication for MASH.

The analysts were focused on doctors recognizing MASH in their diabetic patients and what treatment plans they apply as a result. With analysts predicting strong sales growth for the current year, these insights might significantly increase Rezdiffra’s market potential.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company committed to developing novel treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition with an unmet medical need.

While we acknowledge the potential of MDGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.